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Skin cancer is the most common malignancy in Caucasian popula-
tions. Melanoma, the most serious form of skin cancer, presents a
particularly serious problem as its incidence worldwide continues
to rise (Sinha and Benedict, 1996). The treatment of choice for
recurrent or in transit melanoma metastases of the limb has been
Isolated Limb Perfusion (ILP) since its introduction in 1957
(Creech et al, 1958; Vrouenraets et al, 1996; Duran Garcia et al,
1999). This regional drug administration technique allows concen-
trations of the cytotoxic agent 15–20 times higher than tolerated
systemically to be used (Renard et al, 1995). The drug of choice is
the alkylating agent L-phenylalanine mustard (melphalan), admin-
istered on its own or in combination with other anti-neoplastic
agents, immune-modulators such as TNFa, vasodilators such as
papaverine, or anti-neoangiogenic agents. A complete response
rate (CR) of 54% and an overall response rate (OR) of 79% have
been reported with melphalan used as a single agent (Vrouenraets
et al, 1999). 
Recently ILP has been replaced in some centres by a simplified
method that yields comparable results, Isolated Limb Infusion
(Thompson et al, 1994, 1996, 1998). A diagrammatic representa-
tion of ILI and sampling by microdialysis is shown in Figure 1.
Rapid infusion of the drug into the limb is achieved via percuta-
neous catheters placed in the axial artery and vein of the limb,
followed by recirculation using a syringe and 3-way-tap, and
finally washout of residual drug after 20–30 minutes. A heating
device is incorporated into the external circuit to maintain limb
temperature, but unlike conventional ILP the perfusate is not
oxygenated during ILI. The duration of the entire procedure is
about one hour and it can potentially be tolerated multiple times
even by patients in suboptimal condition. Since 1995 ILI has been
successfully performed on a substantial number of patients not
only for recurrent limb melanoma, but also for Merkel cell carci-
noma and various soft tissue sarcomas in Sydney and Brisbane.
We have recently reported pharmacokinetic parameters of
melphalan during ILI and presented a mathematical model
predicting tissue drug concentrations (Roberts et al, in press). 
A problem associated with both ILI and ILP procedures is treat-
ment-induced post operative limb toxicity. As with all forms of
chemotherapy, the procedures aim to deliver a maximal drug dose at
the highest possible limit of the patient’s tolerance. Thus an associa-
tion of peak drug concentration with limb toxicity would appear
likely, however this has yet to be demonstrated (Vrouenraets et al,
1995). As drug concentrations in different tissues such as muscle,
skin, fat and tumour vary considerably during ILP and ILI (Scott
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Figure 1 Diagrammatic representation of ILI and placement of microdialysis probes 
et al, 1992; Wu et al, 1997a; de Wilt et al, 2000), the respective
concentrations cannot readily be derived from plasma concentra-
tions. To obtain data on drug concentrations in normal tissue of
patients by performing biopsies is not always practical, and data
from tumour biopsies do not reflect drug concentrations in the
surrounding tissue, which may, wholly or in part, cause the post-
operative toxic reaction. The novel technique of microdialysis
allows monitoring of the concentrations of drug in various tissues,
and thus permits the relationship between vascular and tissue drug
concentrations to be described more exactly (Wu et al, 2000). In this
study we have simultaneously monitored plasma concentrations and
measured interstitial and tumour concentrations of melphalan by
microdialysis in patients undergoing ILI. Microdialysate concentra-
tions were then fitted to a pharmacokinetic model that assumes the
microdialysis probe is in the interstitium, with melphalan distribu-
tion occurring from and to the plasma. Potential relationships
between tumour responses, melphalan toxicity and melphalan
pharmacokinetics were then studied. 
PATIENTS AND METHODS 
Patients in the study were treated by ILI between August 1998 and
September 1999 for multiple cutaneous and/or subcutaneous recur-
rences of melanoma on a lower limb (n = 14) or upper limb (n = 1),
malignant fibrous histiocytoma (lower limb, n = 2), osteosarcoma
(lower limb, n = 1) and Merkel cell tumour (lower limb, n = 1) using
melphalan and actinomycin D. The study was approved by the insti-
tutional Ethics Committee and informed consent for the use of the
microdialysis probes during ILI was obtained from all patients
treated. Patient demographic data are shown in Table 1. 
The protocol for ILI was as described previously (Thompson
et al, 1994, 1998). Briefly, venous and arterial catheters were
inserted percutaneously before the procedure via the contra-lateral
groin and their tips positioned in the affected limb. A pneumatic
tourniquet was placed at an appropriate level around the limb of
the anaesthetized and heparinized patient, and if the foot or hand
was not involved with tumour, it was excluded from infusion by
application of an Esmarch rubber bandage. After inflation of the
tourniquet, the melphalan solution was rapidly infused into the
affected limb, recirculated by withdrawal from the venous catheter
and reinjection into the arterial catheter with a syringe using a 3-
way tap. After approximately 30 minutes residual drug was
flushed from the limb with Hartmann’s solution and discarded.
Samples were taken from the venous catheter at appropriate inter-
vals for estimation of drug concentrations, blood gases and pH. 
The post-operative regional toxicity was graded according to the
system proposed by Wieberdink et al (Wieberdink et al, 1982); I: no
visible reaction; II: slight erythema and/or oedema; III: considerable
erythema and/or oedema with some blistering, with or without
slightly disturbed mobility; IV: extensive dermolysis and/or obvious
damage to deep tissues, causing definite functional disturbances, or
threatened or actual compartment compression syndromes. 
Tumour response to chemotherapy was graded and assessed
according to standard WHO criteria: CR (complete response):
complete disappearance of measurable tumour for at least 4
weeks; PR (partial response): reduction in tumour size of 50% or
more; NR (no response): increase of tumour size by more than
25%; stable disease (SD): change of tumour size < 25% to –50%
as compared to pre-therapy conditions. 
Microdialysis 
The principles of sampling by microdialysis have been described
previously (Ungerstedt, 1991; Blochl-Daum et al, 1996; Wu et al,
2000). A diagrammatic representation of the procedure is shown in
Figure 2. In brief, the technique is based on the diffusion ofM
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Table 1 Patient demographic data and data pertinent to ILI 
No Age Weight Vinf Dose Dose Ton Tinf Vrec MD flow Peak CPK/day Reaction  Tumour response  Diagnosis 
(years) (kg) (ml) (mg) (mgm l –1) (min) (min) (ml) (ml min–1) (IU l–1) (Wieberdink) (WHO)
1 56 53.4 4500 35 7.8 58 8 1875 2.1 3740/5 II PR Melanoma 
2 56 69.4 3500 30 8.6 63 2 1450 3.5 170/2 II PR Melanoma 
3 74 59.5 5000 37.5 7.5 60 3 1525 3.5 1584/5 III CR Melanoma 
4 67 82.0 2300 20 8.7 66 2 1900 3.5 331/5 III CR Melanoma 
5 40 87.0 7000 60 8.6 74 5 1600 3.5 374/4 II PR Melanoma 
6 76 95.6 5500 45 8.2 59 5 2025 3.5 1279/4 III PR Melanoma 
7 70 58.0 3500 40 7.9 65 6 1250 2.0. 931/1 II ** Melanoma 
8 70 78.0 1300 45 15.4 64 7 1025 5.0 128/4 II CR Melanoma 
9 64 85.4 4400 35 8.0 63 3 1200 5.0 184/5 II PR Melanoma 
10 72 98.0 12000 27.5 4.1 58 5 1625 5.0 1384/5 II PR Melanoma 
11 43 58.0 8000 20 6.3 68 4 3150 5.0 25/6 III * Melanoma 
12 33 82.0 9000 35 5.6 53 4 1375 5.0 9464/5 III CR Melanoma 
13 69 85.0 7700 50 6.5 67 4 1300 5.0 1159/3 II CR Melanoma 
14 70 96.0 9000 50 5.6 70 5 1600 5.0 1021/4 III PR Melanoma 
15 64 90.0 8500 50 5.9 70 5 1375 5.0 3466/7 III NR Melanoma 
16 71 74.0 4500 50 8.9 65 5 1800 3.5 4127/4 IV PR Malignant fibrous histiocytoma 
17 78 53.0 4500 50 10.0 61 3 1350 3.5 2976/5 III PR Malignant fibrous histiocytoma 
18 76 73.0 6500 50 7.7 37 5 1225 5.0 3673/6 III CR Merkel cell tumour 
19 45 69.0 4500 50 7.8 66 6 1525 3.5 198/7 II * Osteosarcoma 
Mean 62.8 76.1 5850 41.1 7.9 62.5 4.58 1588 1906 
SD 13.5 14.7 2680 11.2 2.3 7.95 1.57 461 2305 
No: patient number; Age: age at time of ILI (years); Weight: body weight at time of ILI (years); Vinf: Volume of limb infused (ml); Dose (mg): total dose of melphalan given; Dose (mgm l –1) melphalan concentration per
ml of infused limb; Ton: period between closing and re-opening of tourniquet; Tinf: time of rapid drug infusion; Vrec: volume of manual recirculation of drug (ml); MD flow: flow rate setting of microdialysis probe (ml min–1);
Probe: type of microdialysis probe used; Peak CPK: peak concentration of CPK (IU l–1); Reaction: regional post-operative toxicity, graded as by Wieberdink; Tumour response: graded as by WHO. CR (complete
response) complete disappearance of measurable tumour for at least 4 weeks; PR (partial response) reduction in tumour size of 50% or more; NR (no response) increase of tumour size by more than 25%; * no
assessment possible – patient moved overseas; ** no assessment possible – patient died of systemic disease; Diagnosis: tumour type. 160 JF Thompson et al
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analytes from the interstitial compartment through the semiperme-
able membrane (cutoff 20 kDalton) of a perfused probe placed in
the tissue. Samples of interstitial fluid obtained by microdialysis
were collected by inserting a sterile, commercially available
microdialysis catheter with a needle subcutaneously into normal or
into tumour tissue of the affected limb (CMA 60 or CMA 70,
CMA, Solna, Sweden). Perfusion fluid (CMA) was pumped
through the catheter with a microdialysis pump (CMA 106 or 107,
CMA or MS26 Daily Rate Syringe Driver, SIMS Graseby,
Watford, UK). The syringe driver was set at a constant flow rate
during the procedure (2, 2.1, 3.47 or 5 ml min–1 perfusion fluid).
Validity of results and recovery of melphalan under these conditions
have been discussed previously (Ungerstedt, 1991; Blochl-Daum
et al, 1996; Wu et al, 2000).
Melphalan dosage 
The mean dose of cytotoxic drug (melphalan) was 7.9 ± 2.3 mg
ml–1 volume of infused limb, with actinomycin D at a concentra-
tion 10–2 that of melphalan. The volume of perfused limbs and of
the hand or foot excluded were determined using a simple water
displacement technique. Data pertinent to patients and ILIs are
summarized in Table 1 
Determination of melphalan concentrations 
The plasma samples taken during ILI and the microdialysate spec-
imens were analysed using a HPLC assay developed in our labora-
tory. The assay, inter and intra assay quality, analytical recovery,
linearity, precision and sensitivity have been described previously
(Wu et al, 1995). Briefly, 100 ml samples were precipitated with
200 ml methanol containing dansyl-arginine (Sigma) as an internal
standard. Fluorescent detection was used with excitation and
emission for melphalan of 265 nm and 360 nm, and 265 and 575
nm for the internal standard. The mobile phase consisted of
methanol-water-glacial acetic acid (25:75:2 v/v), pH 2.7, with 
1-octanosulphonic acid (50 mg 100 ml–1), a flow rate of 2 ml min–1
and an injection volume of 20 ml onto a phenyl column. 
Model development 
The modelling of the melphalan distribution in the plasma of the
limb during ILI has been described in detail elsewhere (Roberts
et al, in press). This model was extended in this analysis to include
the microdialysis site. Figure 2 shows a schematic representation
of the model. In brief, the concentration in the microdialysate (Cmd)
over time is described by the equation. 
Where  Cb is the average perfusate concentration in the two
vascular compartments (Figure 2), where k1 is the rate constant for
transfer from the perfusate to the microdialysate and k2 is the rate
constant for disappearance from the microdialysate (and is the sum
of efflux with microdialysate flow (k2b) plus transfer from micro-
dialysate to perfusate (Figure 2, k2a) ). Other more complex expres-
sions, which recognized exchange into adjunct interstitial space
were considered. These are not presented here as they were found
not to improve the modelling. 
Data analysis 
The non-linear regression program Scientist™ (Micromath
Scientific Software, Salt Lake City) was used to numerically inte-
grate 4 differential equations to fit the melphalan data obtained
from the infusate and wash-out using weighted (1/Yobs) least
squares with Hartley modification of the Gauss–Newton algo-
rithm. The final model fitting was deemed acceptable on the basis
of the regression goodness-of-fit criteria (MSC, model selection
criteria, Scientist) that represented the modified Akaike informa-
tion criteria (Landaw and DiStefano, 1984), a lack of systemic
deviation in the residuals, and the percentage of data accounted for
by the regression (R2 > 0.99). 
AUCs from zero time to the last sampling time were calculated
by trapezoidal rule using Prism 3.0 software. 
RESULTS 
A typical representation of the melphalan concentration profile
during ILI in plasma and subcutaneous microdialysate and in
tumour tissue is shown in Figure 4. Samples were usually
collected over 5 min intervals during infusion and recirculation of
the drug (plasma and microdialysis data) and over 15 min after
time point 75 min (microdialysis). The drug concentrations which
were monitored followed a similar pattern in the 3 tissues, with a
time delay of 5 min for peak concentrations of subcutaneous and
tumour tissues when compared to plasma (Figure 4). 
The results of plasma and microdialysis measurements of the
patients made during ILI are shown in Table 2. One patient was
excluded from calculation of mean tumour melphalan concentra-
tion due to an aberrant value. 
Peak concentrations and AUCs of melphalan were higher in
plasma (24.8 ± 6.1 mg ml–1 and 516 ± 121 mg min–1 ml–1) than in
microdialysis samples from subcutaneous tissue (10.3 ± 5.1 mg
Muscle
PS PS
Perfusate flow rate
Microdialysate flow rate
Vascular space
Microdialysis probe
k1 k2a
k2b
Cp
Cmd
Figure 2 Diagrammatic representation of the pharmacokinetic model used
to describe the distribution of melphalan from plasma into the environment of
the microdialysis probe. PS: permeability surface area product from
perfusate into muscle; Cp: drug concentration in perfusate; Cmd: drug
concentration in microdialysate; k1: exchange coefficient between vascular
and microdialysis spaces; k2a: exchange coefficient between microdialysis
and vascular spaces; k2b: rate constant for melphalan removal from
microdialysis space by microdialysate flow 
d
dt  
Cmd = klCb – k2CmdM
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Table 2 Peak concentrations of melphalan in perfusate, subcutaneous and tumour dialysate and pharmacokinetic parameters 
Peak concentrations
Pharmacokinetic parameters  Perfusate Microdialysis 
Cp Cmd s c Cmd tum
AUCp AUCmd AUCtum k1/k2 PSt
(mgm l –1)( mgm l –1) % (pl) (mgm l –1) % (pl) (ml min–1 ml–1)( ml min–1 ml–1)( ml min–1 ml–1) (ml min–1 100 g–1) 
1 22.3 5.7 25.6 488 137 0.32 4.6 
2 27.2 5.8 21.3 630 418 0.28 0.3 
3 31.3 15.1 48.2 646 420 0.39 1.0 
4 11.8 15.3 130 254 429 0.69 1.0 
5 13.8 4.6 33.3 349 113 0.10 5.5 
7 33.2 13.9 41.9 801 300 0.15 0.6 
8 33.5 9.6 28.7 13.7 40.9 666 497 439 0.48 1.1 
9 23.1 7.5 32.5 480 345 0.54 1.3 
10 24.1 8.4 34.9 503 177 0.20 0.8 
11 17.8 14.6 82.0 14.0 78.7 441 211 * 0.26 0.6 
12 28.3 21 74.2 12.5 44.2 517 18 412 1.0 
13 28.2 12.8 45.4 528 423 0.47 1.9 
14 21.3 17.1 80.3 48.6 228 424 204 1071 0.38 4.0 
15 30.2 10.7 35.4 11.4 37.7 523 376 231 0.38 1.8 
16 23.6 9.5 40.3 511 691 0.65 2.0 
17 22.3 5.2 23.3 2.0 9.0 522 312 78 0.27 1.6 
18 26.5 7.1 26.8 2 7.5 531 307 74 0.31 1.6 
19 28.4 2.2 7.7 1.2 4.2 478 82 9 0.07 2.4 
Mean 24.8 10.3 45.1 8.1 31.7 516 303 207 0.35 1.8 
S D 6.1 5.1 29.3 6.0 26.9 121 168 184 0.18 1.5 
Median 25.3 9.6 35.2 11.4 37.7 514 310 155 0.32 1.5 
Cp: melphalan concentration in perfusate (mg/ml); % (p): percentage of melphalan perfusate concentration; Cmd sc: melphalan concentration in subcutaneous microdialysate (mgm l –1); Cmd tum: melphalan concentration in
tumour microdialysate (mgm l –1); AUC: area under curve; AUCp: area under curve melphalan area under curve in perfusateversus time; AUCmd: melphalan area under curve in microdialysate versus time; AUCtum:
melphalan area under curve in tumour versus time; k1/k2 and PSt are defined in Fig. 2; *insufficient data points; values in italics were excluded from statistics. 162 JF Thompson et al
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ml–1 and 303 ± 168 mg min–1 ml–1) or tumour microdialysis
samples (8.1 ± 6.0 mg ml–1 and 207 ± 184 mg min–1 ml–1, mean ±
standard deviation, Table 2). A higher variability for drug peak
concentrations was observed in tumour tissue (see patient 14,
Table 2, data excluded), and the concentration differences between
subcutaneous and tumour microdialysate were not significant
(P > 0.05, Student’s t-test). There were significant differences,
however, between the peak plasma concentrations and the concen-
trations in subcutaneous and tumour microdialysate (P < 0.001).
The same differences were found for comparison of the AUCs
(Table 2). 
A comparison between predictions of melphalan concentrations
in plasma and interstitial space according to the model with actual
concentrations in two representative studies are shown in Figure 3. 
Peak and median concentrations of melphalan measured during
ILI, melphalan AUCs and pharmacokinetic parameters are
presented in Table 2. The permeability surface area product (PS)
values for transfer of melphalan from perfusate into muscle
showed some degree of variability (1.8 ± 1.5 ml min–1 100 g–1 but
were comparable with earlier results; Roberts et al, in press). The
relationships between measured drug concentrations in plasma and
microdialysate, calculated rations (k1/k2) of the influx rate constant
into microdialysate from perfusate (k1) to efflux from micro-
dialysate (k2), grade of post-operative toxicity and peak CPK
values are shown in Table 2 and Figure 5. No significant relation-
ship between the grade of limb toxicity and melphalan concentra-
tion in plasma or microdialysate could be found (Figure 5 A, C, P
> 0.05). There was no significant difference (P > 0.05) to prove
that the higher ratios of rate constants for influx into a micro-
dialysate from perfusate relative to efflux (k1/k2 value > 0.35) was
associated with elevated limb toxicity, however a larger number of
patients would be needed to decide the question (Figure 5 E). No
relationship was found to exist between peak CPK concentrations
and melphalan peak concentrations in plasma or microdialysate
and between CPK concentrations and the influx from perfusate
into microdialysate to efflux ratio (k1/k2. Figure 5 B, D, F, P >
0.05). 
Analysis of the relationship between tumour response (compar-
ison of poor and good responders, PR and NR, and CR, respec-
tively) to treatment and melphalan concentrations reached during
ILI showed no significant difference with regards to the drug peak
concentrations or AUC. The mean concentrations of subcutaneous
microdialysate, however, were significantly higher (P < 0.01) in
patients that showed complete response (5.34 ± 0.44 mg ml–1)
compared to those that showed only partial or no response (3.72 ±
0.33 mg ml–1). 
DISCUSSION 
In this study, measurements of melphalan concentrations were
made by microdialysis in a group of patients undergoing ILI for
various limb tumours, allowing drug concentration/time profiles to
be constructed, and drug concentrations achieved in different
tissues during ILI to be compared (Figure 4). 
Microdialysis has been successfully employed before for
measuring concentrations of various cytotoxic drugs in the inter-
stitial space of different tissues and tumours in vivo. The transfer
of cytotoxic drugs from plasma to interstitial space and finally
across the tumour endothelium into the intracellular tumour space
is considered a critical step in tumour resistance to chemotherapy
and microdialysis therefore is an important tool in assessing inter-
stitial tissue pharmacokinetics and plasma-to-tissue transfer rates
of cytotoxic drugs in human patients. Clinically, microdialysis has
been used to measure 5-fluorouracil concentrations in breast
cancer patients (Muller et al, 1997; Mader et al, 1998), where high
interstitial tumour concentrations of the drug were reported to be
associated with an improved tumour response, whereas plasma
and subcutaneous drug levels showed no correlation to tumour
response (Muller et al, 1997). Contrasting results have been
reported for breast cancer patients and a patient treated for malig-
nant fibrous histiocytoma (MFH) with methotrexate: analysis of
microdialysates of the breast cancer patients showed no correla-
tion between plasma, interstitial and tumour drug concentrations
(Muller et al, 1998), whereas a close correlation was found
between tumour and systemic levels for both methotrexate and its
major extracellular metabolite 7-hydroxymethotrexate in micro-
dialysate of the MFH patient (Ekstrom et al, 1997). Analysis of
intratumoral and subcutaneous concentrations of carboplatin in
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Figure 5 Relationships between degree of toxicity and (A) melphalan peak concentration in plasma, (C) melphalan peak concentration in microdialysate and
(E) influx and efflux rate constants ratio. Relationships between CPK peak concentration and (B) melphalan peak concentration in plasma, (D) melphalan peak
concentration in microdialysate and (F) influx and efflux rate constants ratio microdialysate of patients treated by systemic administration of
the drug for melanoma did not show any difference between
subcutaneous and tumour tissue (Blochl-Daum et al, 1996). 
Technical differences between ILI and ILP such as lower circu-
lation flow rates, more normothermic conditions and a compara-
tively more hypoxic and acidotic perfusate during ILI (Thompson
et al, 1996) could be responsible. 
In our study, the difference between peak drug concentrations or
AUCs in subcutaneous and tumour microdialysate was not statisti-
cally significant. After exclusion of the unrealistic drug concentration
in tumour dialysate from patient 14 the peak concentration mean was
8.1 ± 6.0 mg ml–1 and there was no difference between drug concen-
trations in the microdialysate in subcutaneous and tumour tissues. 
Analysis of drug concentrations over time in both tissues of 6
patients again showed no differences between tumour and skin
concentrations, which is in agreement with the previous results
from an animal model (Wu et al, 1997a). It remains to be clarified,
however, whether a contradictory report (Klaase et al, 1994)
reflects differences in protocol or, as is more likely, variations in
individual tumour physiology with respect to factors such as their
origin, site, size, and particularly their vascularisation, local blood
flow and degree of necrosis and development of haematoma
during the implantation of microdialysis probe. Also, measure-
ments taken from tumour tissue by microdialysis must generally
be evaluated with great care (small tumour nodules may for
example not cover the entire length of the microdialysis probe). 
No association between the various pharmacokinetic parameters
tested and the treatment-induced post-operative toxicity could be
established. No obvious relation between peak drug concentrations
and limb toxicity has previously been recorded and it was absent in
this study for plasma, subcutaneous and tumour tissue. Drug distrib-
ution parameters such as PS values or exchange rates are theoretical
candidates for involvement in the toxic limb reaction. A weak, non-
significant relation between the ratio for the exchange rates k1/k2 and
the degree of limb toxicity was observed, however, and a study of a
greater number of patients is warranted to either prove the relation-
ship or to exclude it. An association of ‘late’ CPK peaks analogous to
the association between the ‘late peak CPK’ with elevated post-oper-
ative limb toxicity (Lai et al, 1993) could not be established in our
sample (data not shown); however, this result too could possibly be
attributable to the modest sample size. 
In this study there was a significant correlation between the
mean melphalan concentration in subcutaneous microdialysate
over time and the tumour response. There are some possible
reasons why this relationship could be demonstrated for drug
concentrations in healthy tissue but not for tumour microdialysate.
The anatomical subcutaneous environment in which the microdial-
ysis probe is placed is possibly more constant than that of the
probes placed in tumour nodules. The varying degree of tumour
necrosis and resulting changes in contact area of the probe with the
interstitial space could well be responsible for artificially low
results. Differences in micro- and macro-tumour vasculature are
also potential sources of variation. The higher variability of data
values measured in tumour tissue compared with data derived
from subcutaneous tissue or plasma could be indicative of prob-
lems associated with these factors. More data will be needed,
however, to confirm the association of subcutaneous drug concen-
tration with tumour response. 
All patients received actinomycin D at a concentration one
hundredth that of melphalan during ILI. We believe that the
contribution of actinomycin D at this concentration to either
activity or toxicity of the treatment was minimal. Based on our
personal experience comparing outcomes in a large prophylactic
ILP trial carried out by the WHO/EORTC with no actinomycin D;
(Koops et al, 1998) and a large number of therapeutic ILPs with
actinomycin D added; (Thompson et al, 1997). However, to allow
direct comparability of clinical outcomes following therapeutic
ILIs with those following ILPs, we chose not to eliminate the drug
from our protocol. 
It was one aim of this study to use a pharmacokinetic model to
predict drug concentrations in a variety of tissues. The distribution
of solutes into tissues can be described by at least 3 models: (i) a
quasi-instantaneous solute distribution into tissue caused by rapid
diffusion and binding, (ii) a slower distribution of the solute due to
rapid binding to cellular structures and/or carrier proteins; (iii)
slow binding to intracellular sites after rapid cytosolic distribution
of the solute (Weiss et al, 2000). The first model is often used to
describe solute distribution as a 2-compartment dispersion or tank-
in-series models (Roberts et al, 1988). Models (ii) and (iii) are
more complex, taking into account the fact that intracellular drug
distribution may not be instantaneous (Weiss et al, 2000). The
model chosen to represent the drug distribution during ILI was the
less complex 2-compartment tank-in-series model, finding that
criteria such as ‘goodness of fit’ and consistency of parameter esti-
mates (as reflected by coefficients of variation) were within
expected limits. The predicted data for subcutaneous drug concen-
trations varied with respect to initial peak concentrations (Figure 3
B, D). 
Introduction of an adjacent interstitial space to the model
(Figure 2) changed the predicted values and model selection
criteria only marginally. It is possible that these initial peak
concentrations could be attributable to measurements of plasma
concentrations in the subcutaneous microdialysis probes due to
minor, transient haemorrhage from introducing the probes in fully
heparinised patients. 
It is concluded that microdialysis is a technique well suited for
measuring concentrations of cytotoxic drug during the ILI proce-
dure. The results of this study show that the melphalan concentra-
tions in tumour and normal limb tissue during ILI are similar. The
possibility of predicting actual concentrations of cytotoxic drug in
the limb during ILI using our model opens an opportunity for
improved drug dose selection. The combination of predicting
tissue concentrations and monitoring achieved mean drug concen-
trations over time in microdialysate of subcutaneous tissue could
help optimising ILI with regards to post-operative limb morbidity
and tumour response. 
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